BioNTech's Restructuring Gamble: €500M in Savings Pave Way for 2027 Cancer Product Launch
Veröffentlicht: 03.06.2026 um 06:02 Uhr, Redaktion boerse-global.de
The German biotech has entered a make-or-break stretch after emerging from the annual ASCO cancer conference in Chicago with encouraging late-stage data but no immediate catalyst for its battered share price. BioNTech’s stock, hovering around €76.65, has shed nearly a quarter of its value over the past 12 months as the market recalibrates expectations away from the blockbuster Covid vaccine franchise toward an unproven oncology pipeline. What happens between now and year-end will determine whether the company can deliver on its pledge to launch its first cancer product by 2027.
New clinical readouts presented at ASCO strengthened the scientific case for two key candidates. Data from the PRESERVE-004 Phase 2 trial showed that the next-generation anti-CTLA-4 antibody gotistobart (BNT316/ONC-392) produced durable antitumor activity and clinically meaningful survival rates in patients with platinum-resistant ovarian cancer, a notoriously difficult-to-treat population. Updated results were also unveiled for the antibody-drug conjugate Trastuzumab Pamirtecan (BNT323) in recurrent uterine cancer. A third investigational asset, pumitamig, demonstrated encouraging activity in advanced studies. The breadth of the pipeline is striking: BioNTech currently has more than 25 Phase 2 and Phase 3 trials underway, including 13 pivotal studies, and aims to have 15 Phase 3 programmes running by the end of 2026.
That ambition has not gone unnoticed on Wall Street. UBS upgraded the stock from Neutral to Buy on the back of the ASCO data, lifting its price target to $135 from $117. Jefferies, which reiterated its Buy rating and $138 target on June 1, sees differentiation potential from novel combination therapies in non-small cell lung cancer. But caution remains: Bernstein initiated coverage with a Market Perform rating and a $96 target, arguing that the timeline to regulatory approvals is too uncertain to justify a more bullish stance.
Should investors sell immediately? Or is it worth buying BioNTech?
The financial reality behind the scientific progress is sobering. First-quarter 2026 revenue fell to €118.1 million from €182.8 million a year earlier, while the net loss widened to €531.9 million, or €2.10 per diluted share. The company is burning cash aggressively — research and development spending is budgeted at €2.2 billion to €2.5 billion for the full year, with selling, general and administrative costs of €700 million to €800 million. Management nevertheless confirmed its top-line guidance of €2.0 billion to €2.3 billion in 2026 revenue, a figure that still largely reflects residual Covid vaccine income.
To fund that investment without exhausting its war chest, BioNTech is undertaking a radical cost-cutting drive. The plan will see the company vacate its production sites in Idar-Oberstein, Marburg and Tübingen by the end of 2027, and wind down operations in Singapore during the first quarter of 2027. The Marburg facility alone, with eight production suites capable of manufacturing mRNA for up to three billion vaccine doses annually, underscores the scale of the downsizing. Chief Financial Officer Ramón Zapata has said that from the end of 2026, all Covid vaccine supply will be handled exclusively by Pfizer and its existing capacity. The restructuring is expected to generate annual savings of up to €500 million by 2029, with the proceeds redirected into the oncology pipeline.
Alongside the site closures, BioNTech is spinning out its early-stage mRNA research into a separate company, with founders U?ur ?ahin and Ă–zlem TĂĽreci at the helm. A binding agreement for the spin-off is due by the end of the first half of 2026. BioNTech will retain a minority stake and contribute relevant intellectual property, allowing the parent to focus entirely on late-stage oncology assets. The move coincides with a management transition: ?ahin and TĂĽreci plan to step back from their operational roles by the end of this year, handing the reins to a new leadership team tasked with securing approvals in ten cancer indications by 2030.
The company’s balance sheet provides ample runway. At the end of the first quarter, BioNTech held €16.8 billion in cash, cash equivalents and securities. In May the board authorized a share buyback of up to $1 billion, to be executed over twelve months through May 2027. That cushion buys time, but the clock is ticking on the pipeline’s output. At least six late-stage data readouts are expected before year-end, including Phase 3 results for the mRNA cancer immunotherapy BNT113 and interim data from the pivotal PRESERVE-003 trial of gotistobart. Whether those data sets can convert scientific progress into regulatory filings — and eventually into sustainable revenue — will define BioNTech’s next chapter.
Ad
BioNTech Stock: New Analysis - 3 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
